Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

The Finviz API: Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now

Polaryx Therapeutics, Inc.

Contributing Author

Recent Articles by Polaryx Therapeutics, Inc.

Sep-01	Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer PLYX GlobeNewswire
Aug-25	Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial PLYX +6.42% GlobeNewswire
May-28	Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial PLYX +21.51% GlobeNewswire
May-14	Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards PLYX GlobeNewswire
Apr-23	Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference PLYX GlobeNewswire
Apr-21	Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial PLYX -7.54% GlobeNewswire
Apr-15	Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care PLYX GlobeNewswire
Apr-01	Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference PLYX GlobeNewswire
Mar-17	Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) PLYX GlobeNewswire
Mar-12	Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events PLYX -19.27% GlobeNewswire
Feb-27	Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders PLYX GlobeNewswire
Feb-17	Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial PLYX +64.32% GlobeNewswire
Feb-10	Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium PLYX -24.11% GlobeNewswire
Feb-05	Polaryx Therapeutics Welcomes New Members of the Board of Directors PLYX -28.89% GlobeNewswire
Feb-03	Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium as Company Prepares for SOTERIA Trial Launch PLYX -37.29% GlobeNewswire
Feb-02	Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" PLYX GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)